Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.

Details

Ressource 1Download: BIB_FF661047267E.P001.pdf (239.15 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_FF661047267E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.
Journal
Obstetrics and Gynecology Science
Author(s)
Digklia A., Voutsadakis I.A.
ISSN
2287-8572 (Print)
ISSN-L
2287-8572
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
57
Number
6
Pages
457-463
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
OBJECTIVE: Thrombocytosis is an adverse prognostic factor in many types of cancer. We investigated if pre-treatment increased platelet counts provide prognostic information specifically in patients with stage III and IV serous ovarian cancer which is the most common clinical presentation of ovarian cancer.
METHODS: Platelet number on diagnosis of stage III and IV serous ovarian adenocarcinoma was evaluated in 91 patients for whom there were complete follow-up data on progression and survival. Survival and progression free survival of patients with normal platelet counts (150-350 ×10(9)/L) was compared with that of patients with thrombocytosis (>350×10(9)/L) by χ(2) and logrank tests.
RESULTS: The median age of the patients was 66 years-old. From the 91 patients, 52 (57.1%) had normal platelet counts (median, 273×10(9)/L; range, 153-350) at diagnosis of their disease and 39 patients (42.9%) had thrombocytosis (median, 463×10(9)/L; range, 354-631). In the group of patients with normal platelet counts, 24 of the 52 patients had died with a median survival of 43 months (range, 3-100). In the group of patients with thrombocytosis, 24 of the 39 patients had died with a median survival of 23 months (range, 4-79). In the entire group of 91 patients there was a statistically significant difference of the overall survival and progression-free survival between the two groups (logrank test P=0.02 and P=0.007, respectively).
CONCLUSION: In this retrospective analysis of stage III and IV ovarian cancer patients, thrombocytosis at the time of diagnosis had prognostic value regarding overall survival and progression-free survival.
Pubmed
Open Access
Yes
Create date
11/02/2015 15:36
Last modification date
20/08/2019 17:29
Usage data